
ENTX Stock Forecast & Price Target
ENTX Analyst Ratings
Bulls say
Entera Bio is positioned as an attractive oral-peptide platform story because its N-Tab technology tackles a major formulation barrier—protecting peptides in the GI tract while enabling absorption—creating multiple shots on goal beyond the lead asset. EB613 has the strongest fundamentals: it mirrors Forteo’s active ingredient, has shown Phase 2 efficacy and a safety profile broadly similar to Forteo, and benefits from FDA alignment on a single 12-month Phase 3 with a BMD endpoint, which meaningfully de-risks development and could support a faster path to market. The company also has meaningful financial and strategic optionality, with a fully diluted market cap of just ~$565M and ~$255M in pro-forma cash after a July PIPE, while EB613, EB612, EB618, and GLP-2 each address large underserved markets.
Bears say
Entera Bio is burdened by a highly uncertain, single-lead outlook because EB613 is still in clinical development and must clear a 12-month Phase 3 hurdle in a crowded osteoporosis market against entrenched injectables and generics, with risks that PK variability, underwhelming BMD gains, or FDA limitations on labeling could blunt adoption. Financially, the company had just $11.3M in cash and cash equivalents at the end of 2Q 2026 before a $275M private placement in July 2026, but management still expects operations to run into 2030 while profitability is not expected until 2032, implying continued funding risk and future dilution. The bearish view is reinforced by reimbursement and pricing pressure, since payers may resist covering EB613 at a premium to Forteo and could favor lower-cost, established therapies even if the oral format is more convenient.
This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ENTX Analyst Forecast & Price Prediction
Start investing in ENTX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Entera Bio Ltd (ENTX) Forecast
ENTX Analyst Forecast & Price Prediction
Start investing in ENTX
Order type
Buy in
Order amount
Est. shares
0 shares